- Hagens Berman files lawsuit against uniQure, citing harsh FDA criticism.
- The action increases legal and regulatory risk for the gene therapy firm.
- QURE shares face potential downward pressure from growing investor uncertainty.
Back
Back
uniQure Faces Deepening Legal Crisis After FDA Rebuke, Lawsuit
(P1) National shareholder rights law firm Hagens Berman has filed a lawsuit against uniQure N.V. (NASDAQ: QURE) after a series of sharp rebukes from the U.S. Food and Drug Administration, escalating the legal challenges for the gene therapy company.
(P2) "The firm is updating its investigation based on these extraordinary rebukes by FDA officials," Hagens Berman announced in a statement on April 5, 2026.
(P3) The lawsuit follows criticism from the FDA, which has created significant uncertainty around uniQure's regulatory path. Details of the specific FDA rebukes that triggered the lawsuit were not immediately available. The deadline for investors to join the lawsuit is April 13.
(P4) The legal action compounds the risks for uniQure, potentially eroding investor confidence and leading to a sell-off in its stock. The company's stock price is likely to face significant downward pressure as the market digests the full impact of the regulatory and legal battles ahead.
This article is for informational purposes only and does not constitute investment advice.
Features
Resources
© 2026 Finture Development Limited. All rights reserved